Frequency Therapeutics
300 Technology Square, 8th Floor
Cambridge
Massachusetts
02139
United States
Website: http://www.frequencytx.com/
Email: frequencytx@macbiocom.com
About Frequency Therapeutics
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone. Our platform technology is founded on discoveries in progenitor cell biology by Bob Langer, Sc.D. at MIT and Jeff Karp, Ph.D., at Harvard, with contributions from Xiaolei Yin, Ph.D. and other members of the Karp Lab at Harvard and Brigham & Women's Hospital.YEAR FOUNDED:
2015
LEADERSHIP:
Co-founder and CEO: David Luccino
Co-founder and CSO: Chris Loose, Ph.D.
Co-founder and Vice President, Biology and Regenerative Medicine: Will Mclean, Ph.D.
COO: Michael Jirousek, Ph.D.
CMO: Peter C. Weber, M.D., M.B.A.
Senior Vice President, Drug Development and Technical Operations: Raj Manchanda, Ph.D.
TECHNOLOGY:
Please click here for Frequency Therapeutics' technology.
91 articles about Frequency Therapeutics
-
Incoming MassBio Chairman Eyes Improving Gender Diversity Across the State’s Life Sciences Industry
2/27/2018
David Lucchino, chief executive officer of Frequency Therapeutics, is expected to be named the next chairman of MassBio next month. -
Frequency Therapeutics Awarded Grant from JDRF to Generate Glucose-Responsive Insulin-Secreting Cells for Type 1 Diabetes Treatment Using a Small Molecule Approach
2/22/2018
Validation of the PCA Regeneration Platform in additional indications supported by JDRF
-
Three-way Collaboration with the U.S. Army, Harvard University and Frequency Therapeutics to Focus on Progenitor Cell Regeneration in Muscle
2/15/2018
The program is focused on small-molecule therapeutics to address several disease indications and conditions involving muscle.
-
Stem Cell Leaders Join Frequency Therapeutics’ PCA Regenerative Medicine Scientific Advisory Board
12/28/2017
As our lead program for hearing regeneration advances on schedule, we are pleased to formally acknowledge the input from the world’s leading stem cell and regenerative medicine experts who are guiding both our hearing program and additional therapeutic opportunities for our PCA Regeneration platform.
-
Frequency Therapeutics’ First-in-Human Safety Study of FX-322 for Hearing Restoration Achieves All Endpoints
12/21/2017
Frequency Therapeutics today announced the successful completion of a first-in-human study of FX-322, the company’s lead PCA candidate for hearing restoration.
-
Frequency Therapeutics Presented Data At The International Society For Stem Cell Research Supporting Progenitor Cell Activation To Restore Healthy Function In Multiple Tissue Types
6/19/2017
-
Frequency Therapeutics Release: Management Team Strengthened; Executive Level New Hire And Internal Promotion
4/27/2017
-
Massachusetts Startup Frequency Therapeutics Nabs $32 Million
4/12/2017
-
Former Pfizer R&D President Joins Frequency Therapeutics’ SAB
3/30/2017
-
Frequency Therapeutics Announces A Revolutionary Small-molecule Approach To Restore Hearing Published In Cell Reports
2/21/2017
-
Frequency Therapeutics Announces Its Board Of Directors And The Appointment Of Marc A. Cohen As Chairman
1/5/2017